[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@DaiichiSankyoUS Daiichi Sankyo US
Daiichi Sankyo US posts on X about $8750t, $4568t, $6417t, click the the most. They currently have XXXXX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXX -XX%
- X Month XXXXX +36%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX -XX%
Mentions: X #
- X Week X -XX%
- X Month XX +43%
- X Months XX +76%
- X Year XX +867%
Followers: XXXXX #
- X Week XXXXX +0.05%
- X Month XXXXX +0.23%
- X Months XXXXX +1.50%
- X Year XXXXX +1.80%
CreatorRank: undefined #
Social Influence #
Social topic influence $8750t #8, $4568t #1, $6417t #2, click the #989, directed XXXX%
Top accounts mentioned or mentioned by @astrazenecaus @nmx_research @merck @linhnguyen64143 @oncodaily @atoppsummit @ethan_taylor008 @bioworld @afidrocolombia @biolabs @fda @gracequest @biopharmadive @pharmavoice @asco @myesmo @uniteforher @_idmedica @meenu721812551 @inside_pm
Top Social Posts #
Top posts by engagements in the last XX hours
"#BREAKINGNEWS: Daiichi Sankyo joins @BioLabs the leading international innovation platform and network of premier shared laboratory spaces as Platinum Sponsor; providing BioLabs with direct access to Daiichi Sankyo scientific leaders and expertise. Click the image for more"
X Link @DaiichiSankyoUS 2025-10-07T11:15Z 4423 followers, XXX engagements
"#BREAKINGNEWS: Today we announced positive topline results from the TROPION-Breast02 phase X trial for patients with locally recurrent inoperable or metastatic triple negative breast cancer (#TNBC) in collaboration with @AstraZenecaUS. Click the image to learn more. #TNBC"
X Link @DaiichiSankyoUS 2025-10-06T11:18Z 4423 followers, XXX engagements
"#BREAKINGNEWS: The FDA accepted the sBLA for our HER2 directed DXd #ADC followed by a combination regimen for the treatment of adult patients w/ high-risk #HER2 positive early-stage breast cancer prior to surgery in collaboration w/ @AstraZenecaUS. Click to learn more"
X Link @DaiichiSankyoUS 2025-10-01T11:17Z 4423 followers, XXX engagements
"#NEWS: Today we announced positive topline results from the DESTINY-Breast05 phase X trial for patients with high-risk HER2 positive early breast cancer in collaboration w/ @AstraZenecaUS; our second positive phase X trial in HER2 positive early breast cancer. Click for more"
X Link @DaiichiSankyoUS 2025-09-29T12:11Z 4423 followers, XXX engagements
"#NEWS: Throughout @MyESMO we will present more than XX abstracts including two back-to-back presentations during Presidential Symposium I featuring data from the DESTINY-Breast11 & DESTINY-Breast05 phase X trials & late-breaking data from the TROPION-Breast02 phase X trial"
X Link @DaiichiSankyoUS 2025-10-13T11:28Z 4423 followers, XXX engagements